Protalix BioTherapeutics
PLX
PLX
32 hedge funds and large institutions have $1.29M invested in Protalix BioTherapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
47% less capital invested
Capital invested by funds: $2.44M → $1.29M (-$1.15M)
Holders
32
Holding in Top 10
–
Calls
$735K
Puts
$218K
Top Buyers
| 1 | +$257K | |
| 2 | +$63.2K | |
| 3 | +$31K | |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$24.4K |
| 5 |
Renaissance Technologies
New York
|
+$13K |
Top Sellers
| 1 | -$1.33M | |
| 2 | -$641K | |
| 3 | -$74.9K | |
| 4 |
Two Sigma Advisers
New York
|
-$43.2K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$33K |